GSK reported a mixed third-quarter performance on Wednesday, with a notable boost from specialty medicines helping to offset ...

And as recently announced, we have expedited retiring the risk for Zantac. We expect this to result ... And then we've got the oncology strength coming from Jemperli expanded population and ...

“But GSK is showing strength elsewhere in its portfolio with 19% growth in ... settlement to resolve tens of thousands of ...

Following the resolution of the Zantac heartburn medicine legal overhang, analysts are now fretting over the strength of its vaccine sales. Traumatised investors require a long period of peace and ...

“But GSK is showing strength elsewhere in its portfolio with ... of lawsuits in the US over its discontinued heartburn drug Zantac earlier in October.

Within these costs we have included the likely payouts related to the increasingly concerning Zantac litagation ... should hold ample balance sheet strength to support opportunistic acquisitions ...

GSK has also reached an agreement to pay $70 million to resolve the Zantac Qui Tam suit previously filed by Valisure. The arrangement is awaiting final approval from the Department of Justice.